NCT/Study#

NCT04398745 /

GSK-209626

A Phase I Study to Evaluate the Pharmacokinetics and Safety of belantamab mafodotin Monotherapy in Participants with Relapsed and/or Refractory Multiple Myeloma (RRMM) Who Have Normal and Varying Degrees of Impaired Renal Function (DREAMM 12)

A Phase I Study to Evaluate the Pharmacokinetics and Safety of
belantamab mafodotin Monotherapy in Participants with Relapsed and/or Refractory
Multiple Myeloma (RRMM) Who Have Normal and Varying Degrees of Impaired Renal
Function (DREAMM 12)

DISEASE GROUP:
Multiple Myeloma
current phase:
Phase I
STUDY STATUS:
Accepting Patients
Location:
Hackensack, NJ
For More information: